Dysplasia epiphysealis hemimelica (DEH), commonly known as Trevor disease, is a rare non-hereditary epiphyseal disorder, which is characterized by localized overgrowth of osteochondral affecting one or more ossification centers or epiphyses.
This report contains market size and forecasts of Dysplasia Epiphysealis Hemimelica Treatment in Global, including the following market information:
Global Dysplasia Epiphysealis Hemimelica Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Dysplasia Epiphysealis Hemimelica Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Hip Replacement Surgery Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Dysplasia Epiphysealis Hemimelica Treatment include Zimmer Biomet, AstraZeneca, Genentech, Pfizer, Johnson&Johnson, Novartis, Teva and Medacta, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Dysplasia Epiphysealis Hemimelica Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Dysplasia Epiphysealis Hemimelica Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Dysplasia Epiphysealis Hemimelica Treatment Market Segment Percentages, by Type, 2021 (%)
Hip Replacement Surgery
Knee Replacement Surgery
Surgical Excision of Mass with Preservation of the Joint
Global Dysplasia Epiphysealis Hemimelica Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Dysplasia Epiphysealis Hemimelica Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital
Ambulatory Surgical Center
Others
Global Dysplasia Epiphysealis Hemimelica Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Dysplasia Epiphysealis Hemimelica Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Dysplasia Epiphysealis Hemimelica Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Dysplasia Epiphysealis Hemimelica Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Zimmer Biomet
AstraZeneca
Genentech
Pfizer
Johnson&Johnson
Novartis
Teva
Medacta